Document Detail


Ferumoxytol for the treatment of anemia in chronic kidney disease.
MedLine Citation:
PMID:  20126670     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Iron deficiency anemia is a common occurrence in patients with chronic kidney disease and many patients do not respond well to supplementation with oral iron. There are now five intravenous iron preparations available for use in the chronic kidney disease patient, with ferumoxytol being the most recently approved agent. As opposed to previously available intravenous irons, ferumoxytol has the advantage of not needing a test dose, allowing a large dose of iron (510 mg) to be given in a short period of time by bolus injection, and no reported cases of anaphylaxis. Ferumoxytol has advantages for use in the outpatient setting to treat iron deficiency, in patients with chronic kidney disease not yet on dialysis and in patients on peritoneal dialysis. The use of ferumoxytol in the hemodialysis population where thrice weekly intravenous access is the norm is less clear. Cost-effectiveness studies and post-approval studies on ferumoxytol as well as changes in the cost structure of dialysis reimbursement will likely have a large impact on the use of this new agent.
Authors:
Mitchell H Rosner; W Kline Bolton
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  45     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  779-86     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
Affiliation:
Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Iron-Deficiency / drug therapy*,  etiology
Chronic Disease
Clinical Trials as Topic
Ferrosoferric Oxide / adverse effects,  pharmacokinetics,  therapeutic use*
Humans
Infusions, Intravenous
Kidney Diseases / complications*
Chemical
Reg. No./Substance:
1317-61-9/Ferrosoferric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The average body surface area of adult cancer patients in the UK: a multicentre retrospective study.
Next Document:  Romidepsin for the treatment of cutaneous T-cell lymphoma.